Physician profile
Sharleen St Surin-Lord
NPI 1023288156
$219,274.10
in general payments reported to CMS, 2019-2025
33 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $27K · 2021: $20K · 2022: $31K · 2023: $50K · 2024: $17K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Food and Beverage: $6,307 · Travel and Lodging: $4,410 · Consulting Fee: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,650.00 |
| Food and Beverage | $6,306.74 |
| Travel and Lodging | $4,409.77 |
| Consulting Fee | $720.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $160,257.76 | 2019-2025 | Aklief, Twyneo, Oracea |
| Pfizer INC. | $35,890.58 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16,515.18 | 2019-2024 | Duobrii, Altreno, Arazlo |
| Medimetriks Pharmaceuticals, INC. | $1,522.86 | 2019-2025 | Neo-Synalar, Tovet (Emollient Formulation), Ketodan |
| Mayne Pharma Commercial LLC | $1,514.41 | 2019-2022 | |
| Abbvie INC. | $546.83 | 2019-2025 | |
| Ucb, INC. | $413.12 | 2025 | Bimzelx |
| Leo Pharma INC. | $388.77 | 2019-2025 | Anzupgo |
| Genzyme Corporation | $382.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $230.68 | 2025 | |
| Almirall LLC | $226.88 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $151.03 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $137.90 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $124.63 | 2022-2025 | Tremfya |
| Amgen INC. | $112.10 | 2019-2025 | Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $101.81 | 2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $91.75 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.13 | 2025 | Cabtreo |
| Strata Skin Sciences, INC. | $86.85 | 2025 | Xtrac |
| Organon LLC | $68.85 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $60.62 | 2025 | Zoryve |
| Merz North America, INC. | $55.09 | 2023 | |
| Celgene Corporation | $51.26 | 2019 | |
| Kyowa Kirin, INC. | $50.80 | 2021-2025 | |
| Dermavant Sciences, INC. | $47.90 | 2022-2024 | Vtama |
| Epi Health, LLC | $43.23 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $39.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.01 | 2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $19.70 | 2020 | |
| Paratek Pharmaceuticals, INC. | $16.06 | 2025 | Nuzyra |
| Journey Medical Corporation | $6.75 | 2019 | |
| Glenmark Therapeutics INC. | $6.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharleen St Surin-Lord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.